Tissue Regenix Poised for Growth (Analyst Interview)

Tissue Regenix Group Plc (LON:TRX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joined DirectorsTalk. Martin gives us a reminder of what Tissue Regenix does, discusses the poor operating performance, share prices, key messages from the report and thoughts on what will happen to the shares.

Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products.

You might also enjoy reading  Tissue Regenix: Operating leverage
Find more news, interviews, share price & company profile here for:
Hardman & Co

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Hardman & Co Martin Hall
Tissue Regenix Poised for Growth (Analyst Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions